CHICAGO, Nov. 28, 2017 (GLOBE NEWSWIRE) -- Aclara Research, a leader in the development of patient and consumer insights within the cannabis industry, released the preliminary results of their latest study examining Illinois patient usage of medical cannabis and the impact on prescription opioid usage. The study found that 67 percent of Illinois patients stopped using opioid medications after using medical cannabis. The study further went on to find that 30 percent of patients stopped using prescription drugs completely after using medical cannabis.
Aclara partnered with pharmacists, patient advocacy groups and dispensaries to field an online survey of medical cannabis patients residing in Illinois. The team presented the results of the patient survey at the American Society of Consultant Pharmacists (ASCP), and the Midwest Cannabis Education Conference this past November.
Key preliminary findings include:
Carmen Brace of Aclara Research led the patient study in partnership with the following medical cannabis and pharmaceutical experts:
The team will expand this study through qualitative and quantitative research across markets with medical cannabis patients, adult use consumers and medical professionals. Final study results will be released in January 2018. For more information, please connect with Aclara Research, @aclararesearch, on Facebook, LinkedIn and Instagram or visit www.aclararesearch.com.
CONTACT:
Jennifer Podkasik
Arrowhead Communications
630.347.9338
jen@arrowheadsocialpr.com